NOS1 and ovarian cancer: Related to this finding, Zou et al. suggested that NOS1 promoted chemoresistance against cisplatin (DDP) in ovarian cancer cells, providing a potential target to reduce chemoresistance to ovarian cancer therapeutics [36].